MERIDIANParker Hannifin
Live view: Yahoo
Identity (GLEIF Global LEI Index)
| Field | Value | Class |
|---|---|---|
| Legal name | Parker Hannifin | SF |
| LEI | Unavailable | SF |
| Swiss UID | Not in GLEIF record | SF |
| Jurisdiction | Unavailable | SF |
| Legal address | Unavailable | SF |
| Headquarters | Cleveland, Ohio | SF |
| Entity status | Unavailable | SF |
| Geneva connection | unresolved | CM |
Listed securities (SIX Swiss Exchange issuer directory)
| ISIN | Ticker | MIC | Share class | Segment | Accounting standard | Next GM | Auditor | Prov. |
|---|---|---|---|---|---|---|---|---|
| PH | Industrial Machinery & Supplies & Components | — | not announced | — | ⓘ |
Market snapshot
953.21 USD
Stale — 13 days old · delayed per exchange agreement · yahoo
| Metric | Value | Class |
|---|---|---|
| SMA 20 | 960.51 | CM |
| SMA 50 | 910.45 | CM |
| 52-week range position | 79% of range 697.13–1023.02 | CM |
| Trend (SMA20 vs SMA50) | up | CM |
| History depth | 261 daily bars | SF |
Analyst price targets
| Low | Mean | Median | High | Analysts | Provider | As of |
|---|---|---|---|---|---|---|
| 680.0 | 1039.6957 | 1057.0 | 1269.0 | 23 | yahoo_analyst | 2026-07-18T22:54:31Z |
Consensus recommendation (provider-published): buy
Financials (latest reported period)
Most recent reported income-statement figures (company disclosure redistributed by the named source); absent figures stay absent — never estimated.
Period ending 2025-06-30 (annual) · reported in USD
| Metric | Value | Class |
|---|---|---|
| Revenue | 19.9B USD | CD |
| Gross profit | not disclosed | CD |
| Operating income | 4.3B USD | CD |
| EBITDA | not disclosed | CD |
| Net income | 3.5B USD | CD |
| EPS | 27.12 | CD |
Recent company events
News, insider transactions, congressional trading disclosures and analyst-estimate snapshots from connected sources, each with provenance. Analyst estimates are forecasts — never price targets.
| When | Kind | Event | Provenance |
|---|---|---|---|
| 2026-07-16 | news | Earn 8.6% On EMR Stock By Selling Upside You Might Not Miss | ⓘ |
| 2026-07-13 | news | Parker-Hannifin (PH) Recently Broke Out Above the 20-Day Moving Average | ⓘ |
| 2026-07-13 | news | Here's How Much You'd Have If You Invested $1000 in Parker-Hannifin a Decade Ago | ⓘ |
| 2026-07-10 | news | Illinois Tool Stock's Loudest Signal Is The One It Stopped Sending | ⓘ |
| 2026-07-09 | news | 1 Industrials Stock with Promising Prospects and 2 We Find Risky | ⓘ |
| 2026-07-09 | news | 9% Undervalued? Parker Hannifin (PH) After Its Russell 1000 Index Removal | ⓘ |
| 2026-07-08 | news | Parker Hannifin (PH) Stock May Be 22% Above Fair Value After Target Raise | ⓘ |
| 2026-07-08 | news | Should Parker-Hannifin’s (PH) Index Exit and Analyst Praise Shift Its Core Investment Narrative? | ⓘ |
| 2026-07-08 | news | Stocks To Watch: 14 Names Test And Tease New Buy Zones | ⓘ |
| 2026-07-07 | news | 115 years old but driving huge returns in a most modern way | ⓘ |
| 2026-07-06 | news | 2 Reasons to Like PH (and 1 Not So Much) | ⓘ |
| 2026-07-06 | news | Truist Raises its Price Target on Parker-Hannifin (PH) | ⓘ |
Segment & geographic revenue (company disclosures)
Figures parsed from filings and redistributed by the named provider; values are shown as reported and shares are Calculated Metrics with the formula in the column header.
Business segments — period ending 2025-06-30
| Disclosed label | Value (as reported in the filing — no currency asserted) | Share of disclosed total (CM: value ÷ axis total) | Class | Prov. |
|---|---|---|---|---|
| Operating Segments | 13,665,000,000 | 32.9% CM | CD | ⓘ |
| Filtration & Engineered Materials | 5,806,000,000 | 14.0% CM | CD | ⓘ |
| Diversified Industrial | 5,806,000,000 | 14.0% CM | CD | ⓘ |
| Flow & Process Control | 4,518,000,000 | 10.9% CM | CD | ⓘ |
| Motion Systems | 3,341,000,000 | 8.0% CM | CD | ⓘ |
| Commercial Aftermarket | 2,214,000,000 | 5.3% CM | CD | ⓘ |
| Aerospace Systems | 2,214,000,000 | 5.3% CM | CD | ⓘ |
| Commercial Oem | 1,915,000,000 | 4.6% CM | CD | ⓘ |
| Defense Oem | 1,138,000,000 | 2.7% CM | CD | ⓘ |
| Defense Aftermarket | 918,000,000 | 2.2% CM | CD | ⓘ |
Geographic split — period ending 2025-06-30
| Disclosed label | Value (as reported in the filing — no currency asserted) | Share of disclosed total (CM: value ÷ axis total) | Class | Prov. |
|---|---|---|---|---|
| North America | 13,406,000,000 | 67.5% CM | CD | ⓘ |
| Europe | 3,862,000,000 | 19.5% CM | CD | ⓘ |
| Asia Pacific | 2,364,000,000 | 11.9% CM | CD | ⓘ |
| Latin America | 218,000,000 | 1.1% CM | CD | ⓘ |
How the company makes money
Business description and sector are sourced facts (Yahoo assetProfile / Wikidata / Wikipedia — source named per value); the registry-disclosed purpose follows. Disclosed segment/geographic revenue appears in the card above when the issuer reports it; official EDGAR-XBRL and ESEF facts feed the financials card since 2026-07-07. Nothing is estimated in the meantime.
Parker-Hannifin Corporation manufactures and sells motion and control technologies and systems for aerospace and defense, in-plant and industrial equipment, transportation, off-highway, energy, and HVAC and refrigeration markets in North America, Europe, Asia Pacific, and Latin America. The company operates through two segments: Diversified Industrial and Aerospace Systems. SF
source: yahoo:assetProfile · retrieved 2026-07-18
Sector: Industrials peers
Registry-disclosed purpose: Access currently requires credentials — the Swiss registry (Zefix) API returned HTTP 401 anonymously (verified 2026-07-02); registered-purpose text will populate once free Zefix credentials are configured in .env.
Regulators of highest concern
Ranked by maximum applicability of evidence-backed matches; when none exist yet, the jurisdictional supervision context derived from listing venue/domicile is shown instead — labelled, never asserted as a match.
| Authority | Jur. | Matches | Max applicability | Max confidence |
|---|---|---|---|---|
| EU Publications Office (EU law) | EU | 10 | 0.70 | 0.78 |
| us_congress | US | 6 | 0.70 | 0.78 |
| General Services Administration | US | 1 | 0.70 | 0.78 |
Regulatory exposure — matches with evidence
The price-impact column is a LABELLED INFERENCE (EBI): reasoning about whether and why the exposure could bear on the share price, derived from the regulation's type, region and topic and the match layer/direction. It is not an asserted fact and states no magnitude; the Applicability/Confidence/Exposure figures and the linked evidence remain the sourced basis.
| Rule | Instrument | Relationship | Applicability | Confidence | Exposure | Potential price impact (inference) | Review |
|---|---|---|---|---|---|---|---|
| R-SECTOR-TARIFFS_TRADE_REMEDIES | General Services Acquisition Regulation; Acquisition of Information and Communication Tech | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1022R(01): Corrigendum to Commission Delegated Regulation (EU) 2026/1022 of 30 | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1022: Commission Delegated Regulation (EU) 2026/1022 of 30 April 2026 amending | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1457: Commission Implementing Regulation (EU) 2026/1457 of 29 June 2026 on the | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1461: Regulation (EU) 2026/1461 of the European Parliament and of the Council | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1455: Regulation (EU) 2026/1455 of the European Parliament and of the Council | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1463: Council Regulation (EU) 2026/1463 of 25 June 2026 amending Regulation (E | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1465: Council Regulation (EU) 2026/1465 of 25 June 2026 amending Regulation (E | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1422: Commission Implementing Regulation (EU) 2026/1422 of 25 June 2026 amendi | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026R1540: Commission Implementing Regulation (EU) 2026/1540 of 6 July 2026 imposin | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | HR 9601 (119th Congress): To direct the United States Trade Representative to initiate inv | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | S 4883 (119th Congress): A bill to amend the Export Control Reform Act of 2018 to increase | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | S 4840 (119th Congress): Export Control Enforcement and Enhancement Act | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | HR 8169 (119th Congress): Export Control Enforcement and Enhancement Act | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | HR 4326 (119th Congress): To require the Congressional Budget Office to conduct an economi | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | HR 8770 (119th Congress): SAFEGUARDS Act of 2026 | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a US tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
| R-SECTOR-TARIFFS_TRADE_REMEDIES | CELEX:32026D1760: Political and Security Committee Decision (CFSP) 2026/1760 of 14 July 20 | sector_topic_candidate_tariffs_trade_remedies | 0.70 | 0.78 | Insufficient evidence to calculate | EBI Limited direct impact. An indirect topical (candidate) link to a EU tariff / trade-remedy measure: if it applied it could raise input or import costs, or restrict cross-border revenue, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied. | needs_review |
Recent filings — potential impact inputs
A filing flags potential impact only via evidence-backed matching between its disclosed content and tracked measures.
| Filed | Form | Title | Document |
|---|---|---|---|
| 2026-05-01 | 10-Q | 10-Q — Parker-Hannifin Corp | document |
| 2026-04-30 | 8-K | 8-K — Parker-Hannifin Corp | document |
| 2026-03-17 | 8-K | 8-K — Parker-Hannifin Corp | document |
| 2026-01-30 | 10-Q | 10-Q — Parker-Hannifin Corp | document |
| 2026-01-29 | 8-K | 8-K — Parker-Hannifin Corp | document |
| 2025-12-10 | 8-K | 8-K — Parker-Hannifin Corp | document |
| 2025-11-12 | 8-K | 8-K — Parker-Hannifin Corp | document |
| 2025-11-07 | 10-Q | 10-Q — Parker-Hannifin Corp | document |
| 2025-11-06 | 8-K | 8-K — Parker-Hannifin Corp | document |
| 2025-10-28 | 8-K | 8-K — Parker-Hannifin Corp | document |